Skip to main content
. 2018 Jan 23;11:1756285617753365. doi: 10.1177/1756285617753365

Figure 2.

Figure 2.

Mean number of T1 gadolinium-enhanced lesions in all patients at CLARITY baseline and in the cladribine tablet 3.5 mg/kg in CLARITY/placebo in CLARITY Extension and 5.25 mg/kg groups during CLARITY Extension, according to gap duration.

Error bars indicate standard deviation.

CP, cladribine tablet in CLARITY/placebo in CLARITY Extension; Gd+, gadolinium enhanced.